CLEVER CULTURE SYSTEMS LIMITED - Announcements

2.86%

3.6¢

Market Cap $65.33M

Healthcare Biotechnology

Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based... Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based company that provides intelligent automation solutions to microbiology laboratories. The Company has developed a technology, the Automated Plate Assessment System (APAS Independence), using artificial intelligence (AI) and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology is a United States FDA-cleared AI technology for automated culture plate reading. The product is being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS Independence to clinical customers in the United States and selected countries in Europe.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

CC5	First U.S. Clinical Data with APAS Presented at ASM Microbe	PRICE SENSITIVE	24/06/19	658.03KB	Share
CC5	US Market Update	PRICE SENSITIVE	19/06/19	132.39KB	Share
CC5	Information Required Under ASX Listing Rule 3.10.5A	PRICE SENSITIVE	11/06/19	111.28KB	Share
CC5	$5M Oversubscribed Private Placement	PRICE SENSITIVE	05/06/19	1.46MB	Share
CC5	Trading Halt	PRICE SENSITIVE	03/06/19	292.92KB	Share
CC5	APAS Independence Receives US FDA 510(k) Clearance	PRICE SENSITIVE	20/05/19	442.5KB	Share
CC5	Trading Halt	PRICE SENSITIVE	17/05/19	157.96KB	Share
CC5	South Australian Government Loan - $1.0M Drawdown	PRICE SENSITIVE	09/05/19	130.71KB	Share
CC5	Business Update Presentation	PRICE SENSITIVE	30/04/19	2.58MB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/19	289.35KB	Share
CC5	APAS Independence MRSA Study Results Presented at ECCMID	PRICE SENSITIVE	15/04/19	296.45KB	Share
CC5	MRSA Analysis Module - Clinical Study Commenced	PRICE SENSITIVE	02/04/19	133.9KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/19	707.66KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	292.43KB	Share
CC5	US FDA 510k Submitted for APAS Independence	PRICE SENSITIVE	21/12/18	139.09KB	Share
CC5	LBT Receives $1.9 Million R&D Tax Incentive	PRICE SENSITIVE	20/12/18	102.45KB	Share
CC5	LBT Presentation - 121 Tech Investment Conference, Singapore	PRICE SENSITIVE	03/12/18	1.99MB	Share
CC5	CEO Presentation - AGM 2018	PRICE SENSITIVE	28/11/18	1.62MB	Share
CC5	Chairman's Address to Shareholders	PRICE SENSITIVE	28/11/18	94.4KB	Share
CC5	First Placement of APAS Independence into US Lab	PRICE SENSITIVE	26/11/18	123.82KB	Share
CC5	Australian Sales Update	PRICE SENSITIVE	26/11/18	118.52KB	Share
CC5	Quarterly Activities & Cashflow Report - Appendix 4C	PRICE SENSITIVE	31/10/18	410.92KB	Share
CC5	Company Presentation - Australian Non Deal Roadshow	PRICE SENSITIVE	17/09/18	1.97MB	Share
CC5	Preliminary Final Report	PRICE SENSITIVE	30/08/18	1.3MB	Share
CC5	Finalisation of SA Government Loan Facility Agreement	PRICE SENSITIVE	28/08/18	142.02KB	Share
CC5	First Commercial Sale of APAS Independence	PRICE SENSITIVE	22/08/18	143.72KB	Share
CC5	Quarterly Activities & Cash Flow Report - Appendix 4C	PRICE SENSITIVE	30/07/18	444.53KB	Share
CC5	Market Update	PRICE SENSITIVE	29/06/18	47.64KB	Share
CC5	Strategic Plan & Asset Review, WoundVue	PRICE SENSITIVE	06/06/18	166.01KB	Share
CC5	Quarterly Activities & Cash Flow Report - Appendix 4C	PRICE SENSITIVE	26/04/18	444.09KB	Share
CC5	First Placement of APAS Independence into European Lab	PRICE SENSITIVE	24/04/18	175.82KB	Share
CC5	Share Purchase Plan Offer Document	PRICE SENSITIVE	14/03/18	1.12MB	Share
CC5	$7m Oversubscribed Private Placement & Launch of $1m SPP	PRICE SENSITIVE	06/03/18	2.18MB	Share
CC5	Trading Halt	PRICE SENSITIVE	02/03/18	116.35KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/18	901.82KB	Share
CC5	LBT Receives $4m Funding from South Australian Government	PRICE SENSITIVE	19/02/18	167.3KB	Share
CC5	Quarterly Activities & Cash Flow Report (Appendix 4C)	PRICE SENSITIVE	29/01/18	440.74KB	Share
CC5	$2.5M Grant Awarded to Advance WoundVue Development	PRICE SENSITIVE	07/12/17	176.58KB	Share
CC5	Completion of Transaction with Autobio	PRICE SENSITIVE	01/12/17	106.26KB	Share
CC5	St Vincent's Hospital Completes APAS Independence Evaluation	PRICE SENSITIVE	29/11/17	128.93KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/17	207.86KB	Share
CC5	Autobio $2M Placement in LBT & MicroStreak IP Transfer	PRICE SENSITIVE	27/10/17	130KB	Share
CC5	LBT Receives $4.2 Million in R&D Incentives	PRICE SENSITIVE	09/10/17	105.51KB	Share
CC5	ST Vincent's Hospital Commences APAS Automated Evaluation	PRICE SENSITIVE	27/09/17	100.12KB	Share
CC5	Preliminary Final Report	PRICE SENSITIVE	31/08/17	482.73KB	Share
CC5	LBT's WoundVue Prototype to be used at CALHN	PRICE SENSITIVE	08/08/17	111.53KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	10/07/17	409.14KB	Share
CC5	CE Mark Self Certification Finalised for APAS	PRICE SENSITIVE	23/06/17	106.86KB	Share
CC5	ST VINCENTS HOSPITAL MELBOURNE TO BE FIRST APAS TRIAL SITE	PRICE SENSITIVE	21/06/17	155.75KB	Share
CC5	LBT Appointed Distributor for Australia and New Zealand	PRICE SENSITIVE	14/06/17	121.04KB	Share
CC5	Share Purchase Plan Offer	PRICE SENSITIVE	23/05/17	265.63KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/17	209.65KB	Share
CC5	APAS INCLUDED ON THE AUSTRALIAN TGA REGISTER	PRICE SENSITIVE	28/03/17	216.88KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/17	4.68MB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/17	93.69KB	Share
CC5	Completion of Placement	PRICE SENSITIVE	02/12/16	46.33KB	Share
CC5	Trading Halt	PRICE SENSITIVE	30/11/16	280.81KB	Share
CC5	LBT Innovations Granted New Patent for United States	PRICE SENSITIVE	11/11/16	229.58KB	Share
CC5	Appendix 4C - quarterly-LBT.AX	PRICE SENSITIVE	27/10/16	93.98KB	Share
CC5	US FDA GRANTS APPROVAL FOR APAS-LBT.AX	PRICE SENSITIVE	10/10/16	110.43KB	Share
CC5	Preliminary Final Report-LBT.AX	PRICE SENSITIVE	31/08/16	604.89KB	Share
CC5	Appendix 4C - quarterly-LBT.AX	PRICE SENSITIVE	29/07/16	132.11KB	Share
CC5	LBT granted patent in Japan for core APAS technology-LBT.AX	PRICE SENSITIVE	19/05/16	95.51KB	Share
CC5	Cochlear Executive Brent Barnes Appointed CEO of LBT-LBT.AX	PRICE SENSITIVE	09/05/16	118.17KB	Share
CC5	Appendix 4C - quarterly-LBT.AX	PRICE SENSITIVE	26/04/16	324.36KB	Share
CC5	LBT Receives Notice of Allowance for Third Patent-LBT.AX	PRICE SENSITIVE	07/04/16	114.53KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/16	511.39KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	430.6KB	Share
CC5	LBT Innovations Completes U.S. Regulatory Submission	PRICE SENSITIVE	22/12/15	108.57KB	Share
CC5	LBT Concludes APAS Clinical Trial Program	PRICE SENSITIVE	16/11/15	106.1KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	20/10/15	345.88KB	Share
CC5	LBT Receives Notice of Allowance for Second Patent	PRICE SENSITIVE	14/10/15	105.14KB	Share
CC5	LBT CEO Retirement	PRICE SENSITIVE	12/10/15	160.19KB	Share
CC5	APAS Exceeds Expectations in Key U.S. Clinical Trials	PRICE SENSITIVE	07/10/15	241.63KB	Share
CC5	LBT Innovations Market Update	PRICE SENSITIVE	28/08/15	188.76KB	Share
CC5	Preliminary Final Report	PRICE SENSITIVE	27/08/15	570.98KB	Share
CC5	LBT Signs Agreement with bioMerieux	PRICE SENSITIVE	27/08/15	189.48KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/15	167.67KB	Share
CC5	LBT begins key U.S. trial of APAS technology	PRICE SENSITIVE	09/06/15	182.95KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/15	132.39KB	Share
CC5	LBT Granted First U.S. Patent for APAS Technology	PRICE SENSITIVE	26/03/15	84.82KB	Share
CC5	Appendix 4D	PRICE SENSITIVE	27/02/15	4.11MB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	282.9KB	Share
CC5	Notice of Intent re PREVI Isola Licence Agreement	PRICE SENSITIVE	12/01/15	166.98KB	Share
CC5	LBT Completes Australian Clinical Trials of APAS Technology	PRICE SENSITIVE	26/11/14	105.42KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/14	89.08KB	Share
CC5	LBT Awarded $250,000 Grant for Woundvue	PRICE SENSITIVE	20/10/14	119.32KB	Share
CC5	LBT Begins Clinical Trials of APAS Technology	PRICE SENSITIVE	19/09/14	104.52KB	Share
CC5	LBT Innovations receives $3M 2014 R&D tax incentive	PRICE SENSITIVE	04/09/14	124.61KB	Share
CC5	Appendix 4E	PRICE SENSITIVE	29/08/14	144.13KB	Share
CC5	Appendix 4C - quarterly report	PRICE SENSITIVE	31/07/14	90.43KB	Share
CC5	LBT raises A$1.5M in private placement	PRICE SENSITIVE	18/06/14	143.24KB	Share
CC5	Trading Halt	PRICE SENSITIVE	16/06/14	126.29KB	Share
CC5	LBT Innovations receives third $1M milestone payment	PRICE SENSITIVE	11/06/14	100.64KB	Share
CC5	LBT Innovations Introduces Landmark Diagnostic Platform	PRICE SENSITIVE	12/05/14	123.53KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/14	1.03MB	Share
CC5	Response to Price Query	PRICE SENSITIVE	10/04/14	105.39KB	Share
CC5	Appendix 4D Half Year Results	PRICE SENSITIVE	20/02/14	1.17MB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	346.52KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	17/10/13	1MB	Share

CC5 First U.S. Clinical Data with APAS Presented at ASM Microbe
24/06/19	PRICE SENSITIVE	658.03KB	Share
CC5 US Market Update
19/06/19	PRICE SENSITIVE	132.39KB	Share
CC5 Information Required Under ASX Listing Rule 3.10.5A
11/06/19	PRICE SENSITIVE	111.28KB	Share
CC5 $5M Oversubscribed Private Placement
05/06/19	PRICE SENSITIVE	1.46MB	Share
CC5 Trading Halt
03/06/19	PRICE SENSITIVE	292.92KB	Share
CC5 APAS Independence Receives US FDA 510(k) Clearance
20/05/19	PRICE SENSITIVE	442.5KB	Share
CC5 Trading Halt
17/05/19	PRICE SENSITIVE	157.96KB	Share
CC5 South Australian Government Loan - $1.0M Drawdown
09/05/19	PRICE SENSITIVE	130.71KB	Share
CC5 Business Update Presentation
30/04/19	PRICE SENSITIVE	2.58MB	Share
CC5 Appendix 4C - quarterly
29/04/19	PRICE SENSITIVE	289.35KB	Share
CC5 APAS Independence MRSA Study Results Presented at ECCMID
15/04/19	PRICE SENSITIVE	296.45KB	Share
CC5 MRSA Analysis Module - Clinical Study Commenced
02/04/19	PRICE SENSITIVE	133.9KB	Share
CC5 Half Yearly Report and Accounts
26/02/19	PRICE SENSITIVE	707.66KB	Share
CC5 Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	292.43KB	Share
CC5 US FDA 510k Submitted for APAS Independence
21/12/18	PRICE SENSITIVE	139.09KB	Share
CC5 LBT Receives $1.9 Million R&D Tax Incentive
20/12/18	PRICE SENSITIVE	102.45KB	Share
CC5 LBT Presentation - 121 Tech Investment Conference, Singapore
03/12/18	PRICE SENSITIVE	1.99MB	Share
CC5 CEO Presentation - AGM 2018
28/11/18	PRICE SENSITIVE	1.62MB	Share
CC5 Chairman's Address to Shareholders
28/11/18	PRICE SENSITIVE	94.4KB	Share
CC5 First Placement of APAS Independence into US Lab
26/11/18	PRICE SENSITIVE	123.82KB	Share
CC5 Australian Sales Update
26/11/18	PRICE SENSITIVE	118.52KB	Share
CC5 Quarterly Activities & Cashflow Report - Appendix 4C
31/10/18	PRICE SENSITIVE	410.92KB	Share
CC5 Company Presentation - Australian Non Deal Roadshow
17/09/18	PRICE SENSITIVE	1.97MB	Share
CC5 Preliminary Final Report
30/08/18	PRICE SENSITIVE	1.3MB	Share
CC5 Finalisation of SA Government Loan Facility Agreement
28/08/18	PRICE SENSITIVE	142.02KB	Share
CC5 First Commercial Sale of APAS Independence
22/08/18	PRICE SENSITIVE	143.72KB	Share
CC5 Quarterly Activities & Cash Flow Report - Appendix 4C
30/07/18	PRICE SENSITIVE	444.53KB	Share
CC5 Market Update
29/06/18	PRICE SENSITIVE	47.64KB	Share
CC5 Strategic Plan & Asset Review, WoundVue
06/06/18	PRICE SENSITIVE	166.01KB	Share
CC5 Quarterly Activities & Cash Flow Report - Appendix 4C
26/04/18	PRICE SENSITIVE	444.09KB	Share
CC5 First Placement of APAS Independence into European Lab
24/04/18	PRICE SENSITIVE	175.82KB	Share
CC5 Share Purchase Plan Offer Document
14/03/18	PRICE SENSITIVE	1.12MB	Share
CC5 $7m Oversubscribed Private Placement & Launch of $1m SPP
06/03/18	PRICE SENSITIVE	2.18MB	Share
CC5 Trading Halt
02/03/18	PRICE SENSITIVE	116.35KB	Share
CC5 Half Yearly Report and Accounts
26/02/18	PRICE SENSITIVE	901.82KB	Share
CC5 LBT Receives $4m Funding from South Australian Government
19/02/18	PRICE SENSITIVE	167.3KB	Share
CC5 Quarterly Activities & Cash Flow Report (Appendix 4C)
29/01/18	PRICE SENSITIVE	440.74KB	Share
CC5 $2.5M Grant Awarded to Advance WoundVue Development
07/12/17	PRICE SENSITIVE	176.58KB	Share
CC5 Completion of Transaction with Autobio
01/12/17	PRICE SENSITIVE	106.26KB	Share
CC5 St Vincent's Hospital Completes APAS Independence Evaluation
29/11/17	PRICE SENSITIVE	128.93KB	Share
CC5 Appendix 4C - quarterly
31/10/17	PRICE SENSITIVE	207.86KB	Share
CC5 Autobio $2M Placement in LBT & MicroStreak IP Transfer
27/10/17	PRICE SENSITIVE	130KB	Share
CC5 LBT Receives $4.2 Million in R&D Incentives
09/10/17	PRICE SENSITIVE	105.51KB	Share
CC5 ST Vincent's Hospital Commences APAS Automated Evaluation
27/09/17	PRICE SENSITIVE	100.12KB	Share
CC5 Preliminary Final Report
31/08/17	PRICE SENSITIVE	482.73KB	Share
CC5 LBT's WoundVue Prototype to be used at CALHN
08/08/17	PRICE SENSITIVE	111.53KB	Share
CC5 Appendix 4C - quarterly
10/07/17	PRICE SENSITIVE	409.14KB	Share
CC5 CE Mark Self Certification Finalised for APAS
23/06/17	PRICE SENSITIVE	106.86KB	Share
CC5 ST VINCENTS HOSPITAL MELBOURNE TO BE FIRST APAS TRIAL SITE
21/06/17	PRICE SENSITIVE	155.75KB	Share
CC5 LBT Appointed Distributor for Australia and New Zealand
14/06/17	PRICE SENSITIVE	121.04KB	Share
CC5 Share Purchase Plan Offer
23/05/17	PRICE SENSITIVE	265.63KB	Share
CC5 Appendix 4C - quarterly
26/04/17	PRICE SENSITIVE	209.65KB	Share
CC5 APAS INCLUDED ON THE AUSTRALIAN TGA REGISTER
28/03/17	PRICE SENSITIVE	216.88KB	Share
CC5 Half Yearly Report and Accounts
27/02/17	PRICE SENSITIVE	4.68MB	Share
CC5 Appendix 4C - quarterly
31/01/17	PRICE SENSITIVE	93.69KB	Share
CC5 Completion of Placement
02/12/16	PRICE SENSITIVE	46.33KB	Share
CC5 Trading Halt
30/11/16	PRICE SENSITIVE	280.81KB	Share
CC5 LBT Innovations Granted New Patent for United States
11/11/16	PRICE SENSITIVE	229.58KB	Share
CC5 Appendix 4C - quarterly-LBT.AX
27/10/16	PRICE SENSITIVE	93.98KB	Share
CC5 US FDA GRANTS APPROVAL FOR APAS-LBT.AX
10/10/16	PRICE SENSITIVE	110.43KB	Share
CC5 Preliminary Final Report-LBT.AX
31/08/16	PRICE SENSITIVE	604.89KB	Share
CC5 Appendix 4C - quarterly-LBT.AX
29/07/16	PRICE SENSITIVE	132.11KB	Share
CC5 LBT granted patent in Japan for core APAS technology-LBT.AX
19/05/16	PRICE SENSITIVE	95.51KB	Share
CC5 Cochlear Executive Brent Barnes Appointed CEO of LBT-LBT.AX
09/05/16	PRICE SENSITIVE	118.17KB	Share
CC5 Appendix 4C - quarterly-LBT.AX
26/04/16	PRICE SENSITIVE	324.36KB	Share
CC5 LBT Receives Notice of Allowance for Third Patent-LBT.AX
07/04/16	PRICE SENSITIVE	114.53KB	Share
CC5 Half Yearly Report and Accounts
29/02/16	PRICE SENSITIVE	511.39KB	Share
CC5 Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	430.6KB	Share
CC5 LBT Innovations Completes U.S. Regulatory Submission
22/12/15	PRICE SENSITIVE	108.57KB	Share
CC5 LBT Concludes APAS Clinical Trial Program
16/11/15	PRICE SENSITIVE	106.1KB	Share
CC5 Appendix 4C - quarterly
20/10/15	PRICE SENSITIVE	345.88KB	Share
CC5 LBT Receives Notice of Allowance for Second Patent
14/10/15	PRICE SENSITIVE	105.14KB	Share
CC5 LBT CEO Retirement
12/10/15	PRICE SENSITIVE	160.19KB	Share
CC5 APAS Exceeds Expectations in Key U.S. Clinical Trials
07/10/15	PRICE SENSITIVE	241.63KB	Share
CC5 LBT Innovations Market Update
28/08/15	PRICE SENSITIVE	188.76KB	Share
CC5 Preliminary Final Report
27/08/15	PRICE SENSITIVE	570.98KB	Share
CC5 LBT Signs Agreement with bioMerieux
27/08/15	PRICE SENSITIVE	189.48KB	Share
CC5 Appendix 4C - quarterly
31/07/15	PRICE SENSITIVE	167.67KB	Share
CC5 LBT begins key U.S. trial of APAS technology
09/06/15	PRICE SENSITIVE	182.95KB	Share
CC5 Appendix 4C - quarterly
28/04/15	PRICE SENSITIVE	132.39KB	Share
CC5 LBT Granted First U.S. Patent for APAS Technology
26/03/15	PRICE SENSITIVE	84.82KB	Share
CC5 Appendix 4D
27/02/15	PRICE SENSITIVE	4.11MB	Share
CC5 Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	282.9KB	Share
CC5 Notice of Intent re PREVI Isola Licence Agreement
12/01/15	PRICE SENSITIVE	166.98KB	Share
CC5 LBT Completes Australian Clinical Trials of APAS Technology
26/11/14	PRICE SENSITIVE	105.42KB	Share
CC5 Appendix 4C - quarterly
24/10/14	PRICE SENSITIVE	89.08KB	Share
CC5 LBT Awarded $250,000 Grant for Woundvue
20/10/14	PRICE SENSITIVE	119.32KB	Share
CC5 LBT Begins Clinical Trials of APAS Technology
19/09/14	PRICE SENSITIVE	104.52KB	Share
CC5 LBT Innovations receives $3M 2014 R&D tax incentive
04/09/14	PRICE SENSITIVE	124.61KB	Share
CC5 Appendix 4E
29/08/14	PRICE SENSITIVE	144.13KB	Share
CC5 Appendix 4C - quarterly report
31/07/14	PRICE SENSITIVE	90.43KB	Share
CC5 LBT raises A$1.5M in private placement
18/06/14	PRICE SENSITIVE	143.24KB	Share
CC5 Trading Halt
16/06/14	PRICE SENSITIVE	126.29KB	Share
CC5 LBT Innovations receives third $1M milestone payment
11/06/14	PRICE SENSITIVE	100.64KB	Share
CC5LBT Innovations Introduces Landmark Diagnostic Platform
12/05/14	PRICE SENSITIVE	123.53KB	Share
CC5Appendix 4C - quarterly
28/04/14	PRICE SENSITIVE	1.03MB	Share
CC5Response to Price Query
10/04/14	PRICE SENSITIVE	105.39KB	Share
CC5Appendix 4D Half Year Results
20/02/14	PRICE SENSITIVE	1.17MB	Share
CC5Appendix 4C - quarterly
31/01/14	PRICE SENSITIVE	346.52KB	Share
CC5Appendix 4C - quarterly
17/10/13	PRICE SENSITIVE	1MB	Share

REFRESH

First 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.6¢		Change 0.001(2.86%)		Mkt cap ! $65.33M

Open	High	Low	Value	Volume
3.5¢	3.6¢	3.5¢	$18.02K	513.3K

Buyers (Bids)

No.	Vol.	Price($)
7	991682	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.6¢	1072927	5

View Market Depth

No.	Vol.	Price($)
7	991682	0.034
6	971865	0.033
4	504275	0.032
1	32258	0.031
4	618150	0.030

Price($)	Vol.	No.
0.036	1072927	5
0.037	1353817	1
0.039	1128436	4
0.040	3000000	2
0.041	300000	1

Last trade - 15.55pm 21/08/2025 (20 minute delay)


Last 3.6¢		Change 0.001 ( 2.86 %)
Open	High	Low	Volume
3.5¢	3.6¢	3.5¢	84104
Last updated 15.55pm 21/08/2025 ?

CC5 (ASX) Chart

CLEVER CULTURE SYSTEMS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories